Health tech firms PicnicHealth and Roche are expanding their global partnership to speed up neurological disease research. PicnicHealth allows patients to see their health history and contribute their de-identified medical data to clinical research. Roche will use PicnicHealth’s real-world datasets to understand Alzheimer’s disease, Alzheimer’s disease-related dementias, and myasthenia gravis. The data will be used in Roche’s pan-neuroscience patient research study, which is intended to offer information on unmet needs and challenges faced by patients with neurological diseases.
Health technology company PicnicHealth has announced an expansion of its partnership with pharmaceutical giant Roche and its subsidiary Genentech to accelerate neurological disease research through investments in real-world data. The partnership will leverage PicnicHealth’s technology platform, which allows patients to see their health history and contribute their de-identified medical data to clinical research.
Roche will use PicnicHealth’s most recent real-world datasets for Alzheimer’s disease, dementias associated with Alzheimer’s disease, and myasthenia gravis, a chronic autoimmune ailment that causes weakening in the skeletal muscles, to expedite its pan-neuroscience patient research project. The data from this study on unmet needs and challenges patients with neurological diseases experience will help researchers better understand disease progression and staging, as well as the overall impact that a neurological disease has on a patient and his or her care team.
The partnership between PicnicHealth and Roche is part of a larger trend in the healthcare industry, which is increasingly leveraging real-world data to drive innovation and accelerate research. Real-world data refers to data that is generated through routine healthcare delivery, as opposed to data that is generated through clinical trials or other controlled settings.
Real-world data is becoming increasingly important in healthcare because it offers a more complete and accurate picture of patients’ experiences and outcomes in real-world settings. This data can be used to identify unmet needs and challenges, as well as to develop new treatments and interventions that are better tailored to patients’ needs and preferences.
PicnicHealth is a leading provider of real-world data, and the company has raised significant funding over the past few years to support its growth and expansion. Last year, the company raised $60 million in Series C funding, two years after it scored $35 million in equity financing. The company has also formed partnerships with several other healthcare companies, including global biopharmaceutical company Bristol Myers Squibb and CureDuchenne, a global nonprofit dedicated to finding a cure for Duchenne muscular dystrophy.
The partnership between PicnicHealth and Roche is particularly significant because it focuses on neurological diseases, which are among the most challenging and complex conditions to treat. Neurological diseases affect the brain and nervous system, and they can have a wide range of symptoms and complications. These diseases can also be difficult to diagnose and manage, which makes it especially important to leverage real-world data to better understand them and develop more effective treatments.
The partnership between PicnicHealth and Roche is expected to have a significant impact on neurological disease research, as it will enable researchers to access a large and diverse set of real-world data from patients with Alzheimer’s Disease, Alzheimer’s Disease-related dementias, and myasthenia gravis. This data will be used to identify unmet needs and challenges, as well as to develop new treatments and interventions that are better tailored to patients’ needs and preferences.
In addition to its partnership with Roche, PicnicHealth is also working with other healthcare companies to advance real-world data research. For example, the company is partnering with Bristol Myers Squibb to combine datasets to understand patients with obstructive hypertrophic cardiomyopathy better. The company is also partnering with CureDuchenne to bolster the company’s real-world evidence generation for its platform CureDuchenne Link.
